EUVIMEDEUVIMED entdecken
Crossref

Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma

Dongling Zhu, Shuang Song, Sijuan Zou, Dong Kuang, Dongdong Wang, Xiangde Min, Zhaoyan Feng, Yuankai Zhu, Zhaoting Cheng, Siyuan Cheng, Jianyuan Zhou, Ruping Pan und 2 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-024-07062-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Dongling Zhu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Positron Emission Tomography Computed Tomography, Coordination Complexes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To investigate the efficacy of [68Ga]Ga-FAPI-04 PET/CT for assessing viable tumours (VTs) after local regional treatment (LRT) in hepatocellular carcinoma (HCC) patients. The related imaging features of HCC after LRT are preliminarily discussed. METHODS: A cohort of 37 LRT patients with HCC (encompassing 51 lesions) was retrospectively included from a prospective parent study (ChiCTR2000039099), and sequential PET/CT using [18F]FDG and [68Ga]Ga-FAPI-04 was performed. The diagnostic accuracies of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT and multiphasic CT/MRI for detecting VTs after LRT were calculated and analysed. Pathological examination was considered the gold standard for VT diagnosis, and clinical follow-up was used as the reference standard. The SUVmax and tumour-to-background ratio (TBR) derived from [18F]FDG and [68Ga]Ga-FAPI-04 PET/CT were calculated and compared. Moreover, the SUVmax, target-to-normal liver ratio (TNR) of VT, tumour necrosis (TN), benign rim (BR), and normal liver (NL) from different imaging modalities after LRT for HCC were compared. RESULTS: Both the sensitivity (96.0% [24/25] vs. 36.0% [9/25], p 0.05), [68Ga]Ga-FAPI-04 PET/CT and multiphasic CT/MRI complemented each other in some cases. CONCLUSION: [68Ga]Ga-FAPI-04 PET/CT not only presented higher sensitivity and accuracy than [18F]FDG PET/CT for diagnosing VTs after LRT for HCC but also showed comparable diagnostic accuracy and complementary roles with multiphasic CT/MRI. Overall, [68Ga]Ga-FAPI-04 PET/CT may play an essential role in surveillance after LRT for HCC. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2000039099. Registered 17 October 2020.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPositron Emission Tomography Computed TomographyCoordination ComplexesHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultGallium RadioisotopesTreatment OutcomeQuinolines

Stichwörter der Autor:innen

Hepatocellular carcinomaLocal regional treatmentPET/CTViable tumours[68Ga]Ga-FAPI-04

Substanzen

68Ga-FAPIGallium RadioisotopesCoordination ComplexesQuinolines

Autor:innen und Institutionen

  • Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Nuclear Medicine and Minnan PET Center, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. leochen0821@foxmail.com.
  • Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. evazhu@vip.sina.com.

ORCID-Profile: Haojun Chen

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hubei Province

Zitieren

APA

Zhu, D., Song, S., Zou, S., Kuang, D., Wang, D., Min, X., Feng, Z., Zhu, Y., Cheng, Z., Cheng, S., Zhou, J., Pan, R., Chen, H., & Zhu, X. (2025). Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-07062-5

Vancouver

Zhu D, Song S, Zou S, Kuang D, Wang D, Min X, et al. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-07062-5

BibTeX
@article{Zhu2025,
  author = {Zhu, Dongling and Song, Shuang and Zou, Sijuan and Kuang, Dong and Wang, Dongdong and Min, Xiangde and Feng, Zhaoyan and Zhu, Yuankai and Cheng, Zhaoting and Cheng, Siyuan and Zhou, Jianyuan and Pan, Ruping and Chen, Haojun and Zhu, Xiaohua},
  title = {Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET/CT after local regional treatment in patients with hepatocellular carcinoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-024-07062-5}
}
Kostenlos starten →